Nesta página
01HROW preço
02Instantâneo
03Gráfico
04Divisões de Ações
05Sobre
06Desempenho
07Avaliação e rácios
14Lucros
15Fundamentos Completos
16Demonstrações
17Investidores institucionais (13F)
18Ativistas e proprietários de 5%+
19Executivos da empresa
20Participação em ETFs
21Consenso
22Pares
26Minhas Métricas
HROW Harrow, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 10, 2026
$30,48
· % da faixa de 52 semanas
· acima do mínimo
· para alta
$28,54mínima 52 sem
$54,85máxima 52 sem
Capitalização de Mercado (MRQ)
$1.14B
P/E (TTM)
-31.4
EPS (TTM)
$-0.97
Receita (TTM)
$276M
seus distintivos
Intervalo 52 Semanas
$29–$55
Classificação do Analista
BUY
Preço-Alvo
$65
P/E
-31.4
ROE
-114.8%
Margem de Lucro Líquido
-13.5%
Sua barra de distintivos está vazia — fixe uma métrica em qualquer lugar desta página.
HROW Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$30.48
Capitalização de Mercado (MRQ)
$1.14B
P/E (TTM)
-31.4
EPS (TTM)
$-0.97
Receita (TTM)
$276M
ROE (TTM)
-114.8%
Intervalo 52 Semanas
$29–$55
HROW Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
intervalo
barras
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
Divisões de Ações
| Data ex | Desdobramento | Tipo |
|---|---|---|
| 8 de Fevereiro de 2013 | 1-for-5 | Reverso |
| 24 de Fevereiro de 2012 | 1-for-8 | Reverso |
Sobre Harrow, Inc. - Common Stock Visão geral da empresa da Wikipedia
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
Administration and drug pricing advocacy
The company's founder and chief executive officer is Mark L. Baum, a lawyer by training. Baum has been working in the HIV-related pharmacy field since 1999. Baum has been an advocate for drug pricing and patient advocacy, debating former US congressman James Greenwood on this issue at the Oxford Union debating society. In 2016, Baum authored a monograph on drug pricing and has written about pharmaceutical market monopolies in The Wall Street Journal.
Harrow, through its ImprimisRx subsidiary, has sought to create competition for drugs that companies have monopolies through regulatory or other means by marketing new formulations as a compounding pharmacy. This strategy would allow patient access to certain lower cost medication provided, among other conditions, a patient's physician believed such a formulation was best suited for a patient's needs.
In 2015, the company gained international attention when it compounded a pyrimethamine and leucovorin combination formulation which it argued may offer a low-cost, US$1 per pill, "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000 percent by Martin Shkreli and Turing Pharmaceuticals. In December 2015, Express Scripts accepted the company's product into its formulary.
In 2016, it introduced a lower cost version of tiopronin, and was said to have been working on a version of Mylan's EpiPen. The EpiPen competitor's price target was US$100 for a pair of injectors.
In October 2015, Anthony Principi, a former United States Secretary of Veterans Affairs, was elected to the company's board of directors.
ImprimisRx compounding business
Through its compounding subsidiary ImprimisRx, the company was the first pharmaceutical compounding company to make cGMP ophthalmic eye drops and other sterile compounded products available at a national scale through its FDA-registered outsourcing facility.
ImprimisRx's primary business is that of compounding drugs; that is, combining or altering the formulation of existing drugs to market them to specific populations. As of 2015, the company's business model was driven by development and sale of inexpensive alternatives to off-patent medicines where there was previously only a single manufacturer who could therefore charge outsize prices.
In August 2020, ImprimisRx announced that it was expanding its business beyond compounded drugs and that through a partnership with EyePoint Pharmaceuticals, it would begin to sell Dexycu, an FDA-approved steroid product.
As of 2020, Imprimis operated two pharmaceutical production and distribution facilities, both of which are located in Ledgewood, New Jersey. The company has licenses to operate federally, through the US DEA, and through state pharmacy boards in all 50 of the United States.
Litigation
In 2017, after launching a $49 per month low-cost compounded cyclosporine-A formulation as a potential competitor to Restasis and a glaucoma eye drop program called Simple Drops, the company, alongside Sinceres, became the target of a suit from Allergan for claims connected to supposed false and misleading marketing statements.
The company responded, calling Allergan a "professional litigant" and stating, "Allergan, one of the most powerful Big Pharma companies in the world, has filed this lawsuit against one of the smallest pharmaceutical companies in the world, to snuff out any competition to its high drug price strategies. Allergan, a true Goliath, is bent on ensuring that Americans continue to pay the highest possible prices for its drugs."
During the lawsuit, it was revealed that Allergan engaged in significant lobbying to FDA, state boards of pharmacy, and other federal and state agencies to complain about ImprimisRx. In December 2017, ImprimisRx received a warning letter from the FDA, relaying the agency's determination that the marketing of some of the company's eye drops contained false or misleading claims about efficacy and risks, allegedly in violation of federal law.
After a jury trial, Harrow (then Imprimis Pharmaceuticals) was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan having sought $60 million.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
setorHealthcare
indústriaPharmaceuticals
funcionários373
paísUS
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita$272M2016-12-31 → 2025-12-31
EPS$-0.142017-12-31 → 2025-12-31
Fluxo de caixa livre$43M2016-12-31 → 2025-12-31
Margem líquida-13.5%2016-12-31 → 2025-12-31
Avaliação e Proporções
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | HROW | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | -31.4média 5A ≈-115.6 | ≈-115.6 | · | · | |
| P/S (TTM) | 4.1média 5A ≈4.8 | ≈4.8 | · | · | |
| P/B (MRQ) | 75.2média 5A ≈18.8 | ≈18.8 | 3.2 | Sobreavaliado | |
| Preço / FCF (TTM) | 227.8média 5A ≈-53.3 | ≈-53.3 | · | · | |
| Preço / Fluxo de Caixa (TTM) | 182.7média 5A ≈79.0 | ≈79.0 | · | · | |
| Preço / Valor Patrimonial Tangível (MRQ) | -7.1 | · | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | HROW | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Bruta (TTM) | 73.3%média 5A ≈73.2% | ≈73.2% | · | · | |
| Margem Operacional (TTM) | -1.00%média 5A ≈4.1% | ≈4.1% | 2.2% | Fraco | |
| EBITDA Margin (Margem EBITDA) | 11.7%média 5A ≈5.2% | ≈5.2% | 2.4% | Fraco | |
| Margem de Impostos Pré-Tributação (TTM) | -12.1%média 5A ≈-13.6% | ≈-13.6% | 9.0% | Fraco | |
| Margem de Lucro Líquido (TTM) | -13.5%média 5A ≈-14.0% | ≈-14.0% | 4.5% | Fraco | |
| ROA (TTM) | -9.8%média 5A ≈-10.2% | ≈-10.2% | -0.40% | Abaixo da média | |
| ROE (TTM) | -114.8%média 5A ≈-49.8% | ≈-49.8% | -3.7% | Abaixo da média | |
| ROIC | 218.6%média 5A ≈50.7% | ≈50.7% | 7.9% | Primeira linha |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | HROW | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Índice de liquidez corrente (MRQ) | 2.2média 5A ≈3.9 | ≈3.9 | 4.0 | Baixa liquidez | |
| Quick Ratio (Índice de Liquidez Seca) | 1.9média 5A ≈2.3 | ≈2.3 | 2.6 | Abaixo da média |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | HROW | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 36.4%média 5A ≈41.4% | ≈41.4% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 45.4%média 5A ≈41.4% | ≈41.4% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 41.0% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | HROW | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.7média 5A ≈0.7 | ≈0.7 | 0.7 | Primeira linha | |
| Inventory Turnover (Giro de Estoque) | 5.6média 5A ≈4.8 | ≈4.8 | 2.1 | Primeira linha | |
| Receivables Turnover (Giro de Contas a Receber) | 2.4média 5A ≈9.6 | ≈9.6 | 5.1 | Fraco | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$730.0K | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
-255.0%
Próximo relatório
Nov 09, 2026
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 11, 2026 | $-0.46 | $-0.18 | -150.5% |
| 31 de Março de 2026 | Mai 7, 2026 | $-0.74 | $-0.41 | -80.7% |
| 31 de Dezembro de 2025 | $0.17 | $0.38 | -54.8% | |
| 30 de Setembro de 2025 | $0.22 | $0.27 | -18.1% | |
| 30 de Junho de 2025 | $0.13 | $0.01 | — | |
| 31 de Março de 2025 | $-0.50 | $-0.05 | -970.7% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Cost of Revenue | $68M | $49M | $40M | $25M | $18M | $14M | $17M | $17M | $14M | · | · | · | |
| Gross Profit | $204M | $150M | $91M | $63M | $54M | $34M | $34M | $25M | $13M | $10M | $5M | $567.0K | |
| R&D Expense | $21M | $12M | $7M | $3M | $11M | $2M | $2M | $825.0K | $413.0K | $739.0K | $332.0K | $237.0K | |
| SG&A Expense | $153M | $129M | $83M | $58M | $41M | $31M | $33M | $29M | $25M | $18M | $13M | $8M | |
| Operating Expenses | $174M | $142M | $90M | $61M | $53M | $34M | $39M | $30M | $25M | · | · | · | |
| Operating Income | $31M | $9M | $431.0K | $2M | $2M | $385.0K | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M | |
| Interest Expense | · | · | $21M | $7M | $5M | · | · | · | · | · | · | $3.8K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $32.4K | |
| Other Non-op | $47.0K | $-185.0K | $-444.0K | $102.0K | $197.0K | $-73.0K | $630.0K | $103.0K | $-884.0K | $2M | $-1M | $29.0K | |
| Pretax Income | $-1M | $-17M | $-24M | $-14M | $-18M | $-3M | $-117.0K | $15M | $-13M | $-19M | · | · | |
| Income Tax | $4M | $161.0K | $701.0K | $75.0K | $133.0K | $4.0K | $8.0K | · | $-935.0K | $-111.0K | · | $3.0K | |
| Net Income | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| EPS (Basic) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 | $0.01 | $0.67 | $-0.60 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · | |
| Shares (Basic) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | 26,757,451 | 25,895,352 | 25,323,159 | 21,917,570 | 20,027,712 | · | · | · | |
| Shares (Diluted) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | · | 25,895,352 | 26,466,098 | 23,812,045 | 20,027,712 | · | · | · | |
| EBITDA | $32M | $10M | $1M | $3M | $3M | $2M | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $73M | $47M | $74M | $96M | $42M | $4M | $5M | · | $4M | $9M | $3M | $8M | |
| Short-term Investments | · | · | $9M | $6M | $9M | $28M | · | · | · | · | · | · | |
| Receivables | $111M | $116M | $36M | $6M | $4M | $3M | $2M | $2M | $2M | $3M | $840.0K | $81.0K | |
| Inventory | $14M | $11M | $11M | $7M | $4M | $4M | $3M | $2M | $2M | $2M | $1M | $373.0K | |
| Prepaid Expense | $14M | $15M | $10M | $4M | $1M | $2M | $586.0K | $837.0K | $714.0K | $938.0K | $786.0K | $241.0K | |
| Other Current Assets | $2M | $3M | $2M | $118.0K | $92.0K | $190.0K | $105.0K | $125.0K | $124.0K | $106.0K | $119.0K | $35.0K | |
| Current Assets | $212M | $190M | $139M | $118M | $61M | $41M | $36M | $33M | $9M | $15M | $6M | $9M | |
| PP&E (Net) | $3M | $4M | $4M | $3M | $3M | $4M | $5M | $6M | $6M | $7M | $3M | $243.0K | |
| PP&E (Gross) | $15M | $15M | $14M | $13M | $11M | $10M | $11M | $11M | $9M | $9M | $3M | $288.0K | |
| Accum. Depreciation | $12M | $11M | $10M | $9M | $8M | $6M | $5M | $4M | $3M | $1M | $300.0K | $45.0K | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $2M | $2M | $2M | $2M | $332.0K | |
| Intangibles | $175M | $185M | $160M | $24M | $16M | $2M | $2M | $3M | $3M | $3M | $3M | $611.0K | |
| Total Assets | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Accounts Payable | $35M | $39M | $25M | $14M | $6M | $4M | $8M | $6M | $4M | $4M | $3M | $787.0K | |
| Short-term Debt | · | $220M | · | · | · | $4M | $2M | $3M | · | $4M | · | · | |
| Current Liabilities | $96M | $91M | $49M | $19M | $10M | $11M | $12M | $12M | $6M | $10M | $5M | $2M | |
| Capital Leases | $8M | $9M | $7M | $7M | $6M | $7M | $6M | · | $720.0K | $1M | $1.0K | $19.0K | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $936.0K | $1M | · | |
| Total Liabilities | $347M | $320M | $242M | $130M | $87M | $31M | $32M | $25M | $21M | $21M | $16M | $2M | |
| Long-term Debt | $250M | $263M | $247M | $152M | $103M | $20M | · | $23M | $23M | · | · | · | |
| Total Debt | · | · | · | · | · | $3M | $2M | $3M | · | $4M | · | · | |
| Common Stock | $37.0K | $35.0K | $35.0K | $30.0K | $27.0K | $26.0K | $26.0K | $24.0K | $21.0K | $19.0K | $10.0K | $9.0K | |
| Paid-in Capital | $209M | $221M | $205M | $137M | $107M | $105M | $102M | $99M | $91M | $83M | · | · | |
| Retained Earnings | $-157M | $-151M | $-134M | $-109M | $-95M | $-77M | $-74M | $-74M | $-89M | $-77M | $-58M | $-42M | |
| Stockholders' Equity | $52M | $70M | $71M | $28M | $11M | $27M | $28M | $25M | $3M | $6M | $-1M | $8M | |
| Liabilities + Equity | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Shares Outstanding | 37,229,159 | 35,622,214 | 35,168,260 | 29,901,530 | 26,902,763 | 25,749,875 | 25,526,931 | 24,339,610 | 20,623,129 | 18,627,915 | 9,755,678 | 9,258,231 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $1M | $255.0K | $37.0K | |
| Stock-based Comp | $13M | $18M | $16M | $8M | $6M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $-935.0K | $-111.0K | · | · | |
| Amort. of Intangibles | $17M | $12M | $10M | $2M | $161.0K | $167.0K | $209.0K | $235.0K | $364.0K | $351.0K | $355.0K | $48.0K | |
| Other Non-cash | $35M | $-24M | $12M | $7M | $16M | $-2M | · | · | · | · | · | · | |
| Operating Cash Flow | $44M | $-22M | $4M | $2M | $5M | $-1M | $950.0K | $687.0K | $-9M | $-11M | $-11M | $-7M | |
| CapEx | $887.0K | $2M | $1M | $3M | $2M | $862.0K | $1M | $2M | $772.0K | $7M | $-995.0K | $174.0K | |
| Investing Cash Flow | $-5M | $-33M | $-153M | $-2M | $-19M | $-981.0K | $-2M | $-2M | $-961.0K | $-7M | $-5M | $-910.0K | |
| Stock Issued | · | · | $65M | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $-13.0K | |
| Net Stock Activity | · | · | · | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | $-13.1K | |
| Financing Cash Flow | $-13M | $29M | $127M | $54M | $51M | $1M | $-1M | $4M | $5M | $25M | $11M | $599.0K | |
| Net Change in Cash | $26M | $-27M | $-22M | $54M | $38M | $-648.0K | $-2M | $3M | $-5M | $6M | $-6M | $-7M | |
| Taxes Paid | $93.0K | $374.0K | · | $75.0K | $11.0K | $4.0K | $17.0K | $4.0K | $9.0K | $9.0K | $1.0K | $1.0K | |
| Free Cash Flow | $43M | $-24M | $2M | $-892.0K | $3M | $-2M | $-518.0K | $-1M | $-10M | $-4M | $-12M | $-7M | |
| Levered FCF | · | · | $-20M | $-8M | · | · | · | · | · | · | · | · |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% | 70.4% | 67.3% | 60.1% | 49.6% | 50.7% | 46.4% | 34.2% | |
| Operating Margin | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% | 0.79% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| Net Margin | -1.9% | -8.8% | -18.8% | -15.9% | -24.9% | -6.9% | 0.33% | 35.4% | -44.8% | -95.7% | -163.6% | -609.4% | |
| Pretax Margin | -0.50% | -8.7% | -18.2% | -15.8% | -24.7% | -7.0% | -0.24% | 35.4% | -48.3% | · | · | · | |
| EBITDA Margin | 11.7% | 5.1% | 1.1% | 3.6% | 4.4% | 4.6% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| ROA | -1.3% | -5.0% | -10.4% | -11.0% | -23.1% | -5.8% | 0.31% | 39.9% | -46.9% | -92.3% | -130.5% | -77.8% | |
| ROE | -8.4% | -24.9% | -49.6% | -72.5% | -93.6% | -12.2% | 0.64% | 117.8% | -265.0% | -756.4% | -470.0% | -87.0% | |
| ROIC | 218.6% | 12.8% | 0.63% | 7.0% | 14.4% | 1.3% | · | · | -431.5% | · | · | · |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 | 3.7 | 3.0 | 2.8 | 1.5 | 1.5 | 1.1 | 5.8 | |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 | 0.6 | 0.2 | 0.2 | 1.0 | 1.2 | 0.7 | 5.3 | |
| Debt / Equity | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | 0.6 | · | · | |
| Interest Coverage | · | · | 0.0 | 0.3 | · | · | · | · | · | · | · | -2670.2 |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.6 | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 | 0.8 | 0.1 | |
| Inventory Turnover | 5.6 | 4.6 | 4.6 | 4.7 | 4.5 | 4.0 | 6.5 | 8.1 | · | · | · | · | |
| Receivables Turnover | 2.4 | 2.6 | 6.1 | 16.5 | 20.3 | 20.9 | 26.1 | 24.0 | 12.0 | 10.6 | 21.1 | 40.8 |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.41 | $1.96 | $2.01 | $0.92 | $0.42 | $1.06 | $1.09 | $1.02 | $0.13 | $0.35 | $-0.14 | $0.88 | |
| Revenue / Share | $7.41 | $5.60 | $3.99 | · | · | $1.89 | $1.93 | $1.74 | · | · | · | · | |
| Cash Flow / Share | $1.19 | $-0.62 | $0.12 | · | · | $-0.04 | $0.04 | $0.03 | · | · | · | · | |
| Cash / Share | $1.96 | $1.33 | $2.11 | · | $1.57 | $0.16 | · | · | $0.19 | $0.48 | $0.28 | $0.89 | |
| EPS (TTM) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 36.4% | 53.3% | 46.9% | 22.2% | 48.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 45.4% | 40.2% | 38.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 41.0% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Net Income TTM | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| Market Cap | $1.82B | $1.20B | $394M | $441M | $232M | $177M | $199M | $138M | $35M | $47M | $68M | $69M | |
| Enterprise Value | · | · | · | · | · | $175M | · | · | · | $42M | · | · | |
| P/E | -350.0 | -68.5 | -14.9 | -28.9 | · | -52.8 | 778.0 | 9.3 | -2.8 | · | · | · | |
| P/S | 6.7 | 6.0 | 3.0 | 5.0 | 3.2 | 3.6 | 3.9 | 3.3 | 1.3 | 2.3 | 7.0 | 41.8 | |
| P/B | 34.8 | 17.2 | 5.6 | 16.0 | 20.6 | 6.5 | 7.2 | 5.6 | 13.4 | 7.2 | -48.8 | 8.5 | |
| P / Tangible Book | · | · | · | 124.7 | · | 7.1 | · | · | · | · | · | · | |
| P / Cash Flow | 41.6 | -53.8 | 102.6 | 258.9 | 45.7 | -160.6 | 209.1 | 201.6 | -4.0 | -4.2 | -6.1 | -9.8 | |
| P / FCF | 42.4 | -50.2 | 165.5 | -494.8 | 70.5 | -90.0 | -383.4 | -128.1 | -3.7 | -10.8 | -5.6 | -9.6 | |
| EV / EBITDA | · | · | · | · | · | 77.3 | · | · | · | -2.6 | · | · | |
| EV / FCF | · | · | · | · | · | -89.3 | · | · | · | -9.6 | · | · | |
| EV / Revenue | · | · | · | · | · | 3.6 | · | · | · | 2.1 | · | · | |
| Earnings Yield | -0.29% | -1.5% | -6.7% | -3.5% | · | -1.9% | 0.13% | 10.7% | -35.3% | · | · | · |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $44M | $89M | $72M | $64M | $48M | $67M | $49M | $49M | $35M | $36M | $34M | $33M | $26M | $20M | $23M | |
| Cost of Revenue | $20M | $17M | $18M | $18M | $16M | $16M | $14M | $12M | $13M | $11M | $11M | $10M | $10M | $8M | $6M | $7M | |
| Gross Profit | $50M | $27M | $71M | $54M | $48M | $32M | $53M | $37M | $36M | $24M | $25M | $24M | $23M | $18M | $14M | $16M | |
| R&D Expense | $8M | $6M | $12M | $3M | $3M | $3M | $5M | $2M | $3M | $2M | $3M | $1M | $1M | $734.0K | $703.0K | $775.0K | |
| SG&A Expense | $53M | $43M | $43M | $36M | $33M | $41M | $35M | $34M | $32M | $29M | $26M | $21M | $20M | $16M | $15M | $15M | |
| Operating Expenses | $61M | $49M | $55M | $39M | $36M | $44M | $40M | $36M | $35M | $31M | $30M | $22M | $21M | $17M | $16M | $16M | |
| Operating Income | $-11M | $-22M | $16M | $15M | $11M | $-11M | $13M | $1M | $2M | $-7M | $-5M | $2M | $2M | $1M | $-2M | $-94.0K | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $5M | · | $6M | $6M | $5M | $2M | $2M | |
| Other Non-op | $0 | · | $7M | $61.0K | $-6.0K | $-7M | $6M | $4.0K | $46.0K | $-7M | $-100.0K | $-195.0K | $-178.0K | $29.0K | · | · | |
| Pretax Income | $-17M | $-28M | $10M | $1M | $5M | $-18M | $6M | $-4M | $-6M | $-14M | $-10M | $-3M | $-4M | $-7M | $1M | $-6M | |
| Income Tax | $0 | $25.0K | · | · | $0 | · | $-514.0K | $20.0K | $655.0K | · | $-535.0K | $2M | $-15.0K | $-288.0K | $0 | $35.0K | |
| Net Income | $-17M | $-28M | $7M | $1M | $5M | $-18M | $7M | $-4M | $-6M | $-14M | $-9M | $-4M | $-4M | $-7M | $1M | $-6M | |
| EPS (Basic) | $-0.46 | $-0.74 | $0.19 | $0.03 | $0.14 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| EPS (Diluted) | $-0.46 | $-0.74 | $0.20 | $0.03 | $0.13 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| Shares (Basic) | 37,350,401 | 37,231,321 | · | 37,145,440 | 36,790,306 | 35,826,452 | · | 35,702,200 | 35,618,977 | 35,469,638 | · | 34,255,197 | 30,458,677 | 30,289,730 | · | 27,349,642 | |
| Shares (Diluted) | 37,350,401 | 37,231,321 | · | 38,875,005 | 38,853,855 | 35,826,452 | · | 35,702,200 | 35,618,977 | 35,469,638 | · | 34,255,197 | 30,458,677 | 30,289,730 | · | 27,349,642 | |
| EBITDA | $-11M | $-22M | · | $15M | $12M | $-11M | · | $1M | $2M | $-7M | · | $2M | $2M | $1M | · | $-94.0K |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84M | $95M | $73M | $74M | $53M | $67M | $47M | $73M | $71M | $69M | · | $66M | · | · | $96M | $45M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $7M | · | $8M | $7M | $8M | $6M | $4M | |
| Receivables | $119M | $101M | $111M | $78M | $79M | $77M | $116M | $54M | $52M | $29M | · | $18M | $18M | $12M | $6M | $7M | |
| Inventory | $17M | $16M | $14M | $13M | $12M | $11M | $11M | $10M | $9M | $11M | · | $9M | $9M | $9M | $7M | $5M | |
| Prepaid Expense | $10M | $14M | $14M | $13M | $12M | $15M | $15M | $11M | $7M | $10M | · | $9M | $4M | $4M | $4M | $3M | |
| Other Current Assets | $1M | $1M | $2M | $3M | $3M | $3M | $3M | $1M | $1M | $2M | · | $118.0K | $427.0K | $118.0K | $118.0K | $73.0K | |
| Current Assets | $229M | $226M | $212M | $178M | $155M | $170M | $190M | $147M | $139M | $125M | · | $110M | $60M | $52M | $118M | $64M | |
| PP&E (Net) | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | · | $4M | $4M | $4M | $3M | $3M | |
| PP&E (Gross) | · | · | $15M | $15M | $15M | $15M | $15M | $15M | $14M | $14M | · | $13M | $13M | $13M | $13M | $12M | |
| Accum. Depreciation | · | · | $12M | $12M | $12M | $11M | $11M | $11M | $11M | $10M | · | $10M | $10M | $9M | $9M | $9M | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | · | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | |
| Intangibles | $176M | $181M | $175M | $172M | $177M | $181M | $185M | $189M | $155M | $157M | · | $163M | $150M | $152M | $24M | $20M | |
| Total Assets | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Accounts Payable | $26M | $26M | $35M | $19M | $23M | $37M | $39M | $25M | $22M | $15M | · | $13M | $18M | $14M | $14M | $14M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $59.0K | · | · | · | · | |
| Short-term Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $102M | $91M | $96M | $65M | $249M | $187M | $91M | $95M | $54M | $42M | · | $19M | $23M | $18M | $19M | $18M | |
| Capital Leases | $7M | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $7M | $7M | · | $7M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $402M | $391M | $347M | $316M | $296M | $308M | $320M | $294M | $248M | $235M | · | $211M | $202M | $196M | $130M | $98M | |
| Long-term Debt | · | $300M | $250M | $347M | $251M | $257M | · | $231M | $236M | $243M | · | $252M | $240M | $244M | · | $98M | |
| Total Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $37.0K | $37.0K | $37.0K | $37.0K | $36.0K | $35.0K | $35.0K | $35.0K | $35.0K | $35.0K | · | $35.0K | $30.0K | $30.0K | $30.0K | $27.0K | |
| Paid-in Capital | $217M | $213M | $209M | $210M | $214M | $226M | $221M | $216M | $212M | $208M | · | $200M | $143M | $138M | $137M | $112M | |
| Retained Earnings | $-201M | $-184M | $-157M | $-163M | $-164M | $-169M | $-151M | $-158M | $-154M | $-147M | · | $-125M | $-120M | $-116M | $-109M | $-111M | |
| Stockholders' Equity | $15M | $29M | $52M | $47M | $50M | $56M | $70M | $58M | $59M | $61M | · | $76M | $22M | $22M | $28M | $1M | |
| Liabilities + Equity | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Shares Outstanding | 37,484,233 | 37,269,400 | 37,229,159 | 37,034,582 | 36,714,679 | 35,654,171 | 35,622,214 | 35,611,365 | 35,479,492 | 35,380,955 | · | 35,117,621 | 30,276,938 | 30,056,370 | 29,901,530 | 27,074,307 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $460.0K | $455.0K | $330.0K | $326.0K | $347.0K | $312.0K | $321.0K | $351.0K | $301.0K | $296.0K | $435.0K | $405.0K | $398.0K | $225.0K | $387.0K | $247.0K | |
| Stock-based Comp | $4M | $4M | $4M | $3M | $875.0K | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $5M | $2M | $2M | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | $20.0K | · | · | · | · | $0 | $-288.0K | · | · | |
| Amort. of Intangibles | $6M | $5M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $3M | $2M | $378.0K | $398.0K | |
| Other Non-cash | · | · | · | · | · | $33M | · | · | · | $4M | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-9M | $8M | $17M | $-803.0K | $20M | $-18M | $3M | $-3M | $-5M | $9M | $-1M | $5M | $-8M | $-4M | $-410.0K | |
| CapEx | $491.0K | $194.0K | $341.0K | $210.0K | $166.0K | $170.0K | $555.0K | $604.0K | $344.0K | $92.0K | $194.0K | $520.0K | $250.0K | $496.0K | $878.0K | $1M | |
| Investing Cash Flow | $-534.0K | $-18M | $-5M | $-225.0K | $-293.0K | $-212.0K | $-38M | $-597.0K | $5M | $-110.0K | $-203.0K | $-20M | $-1M | $-131M | $-5.0K | $-1M | |
| Financing Cash Flow | $-466.0K | $49M | $-5M | $5M | $-13M | $23.0K | $30M | $-721.0K | $73.0K | $-809.0K | $-18.0K | $64M | $189.0K | $62M | $55M | $0 | |
| Net Change in Cash | $-11M | $22M | $-1M | $21M | $-14M | $19M | $-25M | $2M | $2M | $-6M | $8M | $43M | $4M | $-77M | $51M | $-1M | |
| Taxes Paid | · | · | $55.0K | $0 | $0 | $38.0K | · | · | · | · | · | · | · | · | $0 | $35.0K | |
| Free Cash Flow | · | $-9M | · | · | · | $19M | · | · | · | $-5M | · | · | · | $-9M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-13M | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.3% | 61.2% | · | 75.3% | 74.5% | 67.5% | · | 75.6% | 74.4% | 69.5% | · | 70.6% | 70.1% | 68.3% | · | 70.5% | |
| Operating Margin | -15.6% | -50.0% | · | 20.6% | 17.9% | -23.5% | · | 2.7% | 3.1% | -20.0% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| Net Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | -37.2% | · | -8.6% | -13.2% | -39.2% | · | -12.8% | -12.6% | -25.4% | · | -28.3% | |
| Pretax Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | · | · | -8.5% | -11.9% | -39.2% | · | -8.3% | -12.7% | -26.6% | · | -28.2% | |
| EBITDA Margin | -15.6% | -50.0% | · | 21.0% | 18.4% | -22.8% | · | 2.7% | 3.1% | -19.2% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| ROA | -4.5% | -7.0% | · | 0.29% | 1.5% | -5.4% | · | -1.3% | -2.4% | -5.3% | · | -2.3% | -2.6% | -4.2% | · | -6.4% | |
| ROE | -53.3% | -64.8% | · | 1.9% | 9.2% | -30.4% | · | -6.3% | -16.0% | -32.9% | · | -11.4% | -30.0% | -41.5% | · | -72.6% | |
| ROIC | -72.4% | -77.0% | · | · | · | · | · | 2.3% | 2.9% | · | · | 3.5% | 10.5% | 5.3% | · | -7.8% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.5 | · | 2.7 | 0.6 | 0.9 | · | 1.5 | 2.6 | 3.0 | · | 5.8 | 2.6 | 2.9 | · | 3.5 | |
| Quick Ratio | 2.0 | 2.1 | · | 2.3 | 0.5 | 0.8 | · | 1.3 | 2.3 | 2.5 | · | 4.9 | 1.1 | 1.1 | · | 3.0 | |
| Debt / Equity | · | · | · | 5.2 | 3.7 | 1.9 | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.3 | · | 0.3 | 0.4 | 0.3 | · | -0.1 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.4 | · | 1.3 | 1.4 | 1.1 | · | 1.4 | 1.5 | 1.2 | · | 1.5 | |
| Receivables Turnover | 0.7 | 0.5 | · | 1.1 | 1.0 | 0.9 | · | 1.4 | 1.4 | 1.7 | · | 2.7 | 2.7 | 2.9 | · | 4.2 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.41 | $0.77 | · | $1.27 | $1.35 | $1.58 | · | $1.63 | $1.65 | $1.71 | · | $2.16 | $0.74 | $0.73 | · | $0.04 | |
| Revenue / Share | $1.89 | $1.19 | · | $1.84 | $1.64 | $1.34 | · | $1.38 | $1.37 | $0.98 | · | $1.00 | $1.10 | $0.86 | · | · | |
| Cash Flow / Share | · | $-0.24 | · | · | · | $0.55 | · | · | · | $-0.13 | · | · | · | $-0.27 | · | · | |
| Cash / Share | $2.24 | $2.54 | · | $2.01 | $1.44 | $1.87 | · | $2.04 | $2.00 | $1.94 | · | $1.87 | · | · | · | $1.66 | |
| EPS (TTM) | $-0.97 | $-0.38 | · | $-0.15 | $-0.30 | $-0.61 | · | $-0.94 | $-0.95 | $-0.91 | · | $-0.44 | $-0.55 | $-0.64 | · | · |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $276M | $269M | · | $250M | $228M | $213M | · | $169M | $154M | $139M | · | $114M | $103M | $93M | · | $88M | |
| Net Income TTM | $-37M | $-15M | · | $-5M | $-10M | $-22M | · | $-33M | $-34M | $-31M | · | $-14M | $-16M | $-18M | · | $-23M | |
| Market Cap | $1.59B | $1.31B | · | $1.78B | $1.12B | $948M | · | $1.60B | $741M | $468M | · | $505M | $576M | $636M | · | $327M | |
| Enterprise Value | · | · | · | $1.95B | $1.25B | $990M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -43.8 | -92.8 | · | -321.2 | -101.8 | -43.6 | · | -47.8 | -22.0 | -14.5 | · | -32.7 | -34.6 | -33.1 | · | · | |
| P/S | 5.8 | 4.9 | · | 7.1 | 4.9 | 4.5 | · | 9.5 | 4.8 | 3.4 | · | 4.4 | 5.6 | 6.9 | · | 3.7 | |
| P/B | 104.7 | 45.8 | · | 38.0 | 22.6 | 16.8 | · | 27.6 | 12.7 | 7.7 | · | 6.7 | 25.7 | 29.1 | · | 268.5 | |
| P / Cash Flow | · | -146.1 | · | · | · | 48.2 | · | · | · | -101.1 | · | · | · | -77.4 | · | · | |
| EV / Revenue | · | · | · | 7.8 | 5.5 | 4.7 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -2.3% | -1.1% | · | -0.31% | -0.98% | -2.3% | · | -2.1% | -4.5% | -6.9% | · | -3.1% | -2.9% | -3.0% | · | · |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $272M | $200M | $130M | $89M | $72M |
| Margem Bruta % | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% |
| Margem Operacional % | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% |
| Lucro líquido | $-5M | $-17M | $-24M | $-14M | $-18M |
| EPS Diluído | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 |
| Índice de Liquidez Seca | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $43M | $-24M | $2M | $-892.0K | $3M |
Investidores institucionais (13F) 242 declarantes · $1.1B total · Em 30 de Setembro de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Detentores
242
Valor detido
$1.1B
Novas posições
41
Posições encerradas
34
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 41 (-6 vs trimestre anterior) | 34 (+4 vs trimestre anterior) | 80 (+11 vs trimestre anterior) | 69 (-9 vs trimestre anterior) | -305K |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $116.372.768 | 2.740.117 | 10,90% | Ações |
| Opaleye Management Inc. | $101.928.000 | 2.400.000 | 9,55% | Ações |
| VANGUARD GROUP INC | $94.162.467 | 1.921.683 | 8,82% | Ações |
| Private Capital Management, LLC | $67.899.762 | 1.598.770 | 6,36% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $60.188.994 | 1.417.212 | 5,64% | Ações |
| Deep Track Capital, LP | $41.153.430 | 969.000 | 3,86% | Ações |
| STATE STREET CORP | $39.917.043 | 939.888 | 3,74% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $38.466.487 | 905.560 | 3,60% | Ações |
| BAMCO INC /NY/ | $34.373.094 | 809.350 | 3,22% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31.550.963 | 742.900 | 2,96% | Opção de compra |
| DIMENSIONAL FUND ADVISORS LP | $28.325.286 | 667.036 | 2,65% | Ações |
| Divisadero Street Capital Management, LP | $18.650.913 | 439.155 | 1,75% | Ações |
| CITADEL ADVISORS LLC | $16.622.758 | 391.400 | 1,56% | Opção de compra |
| RICE HALL JAMES & ASSOCIATES, LLC | $16.459.036 | 387.545 | 1,54% | Ações |
| MARSHALL WACE, LLP | $15.689.905 | 369.435 | 1,47% | Ações |
| CITADEL ADVISORS LLC | $15.283.849 | 359.874 | 1,43% | Ações |
| NORTHERN TRUST CORP | $13.726.559 | 323.206 | 1,29% | Ações |
| Schonfeld Strategic Advisors LLC | $13.574.473 | 319.625 | 1,27% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13.531.367 | 318.610 | 1,27% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11.623.869 | 273.696 | 1,09% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $9.998.202 | 235.418 | 0,94% | Ações |
| CITADEL ADVISORS LLC | $9.895.510 | 233.000 | 0,93% | Opção de venda |
| Westside Investment Management, Inc. | $9.515.477 | 224.051 | 0,89% | Ações |
| FirstWave Capital Management LLC | $9.002.833 | 211.981 | 0,84% | Ações |
| Blackhawk Capital Partners, LLC | $8.631.645 | 203.241 | 0,81% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8.074.227 | 190.116 | 0,76% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.827.221 | 184.300 | 0,73% | Opção de venda |
| JANE STREET GROUP, LLC | $7.772.010 | 183.000 | 0,73% | Opção de compra |
| STIFEL FINANCIAL CORP | $7.682.532 | 180.893 | 0,72% | Ações |
| GOLDMAN SACHS GROUP INC | $6.573.380 | 154.777 | 0,62% | Ações |
| ROYCE & ASSOCIATES LP | $6.565.310 | 154.587 | 0,62% | Ações |
| Crawford Fund Management, LLC | $6.035.836 | 142.120 | 0,57% | Ações |
| Ikarian Capital, LLC | $5.766.364 | 135.775 | 0,54% | Ações |
| Advantage Alpha Capital Partners LP | $5.374.624 | 111.553 | 0,50% | Ações |
| MORGAN STANLEY | $5.105.094 | 120.204 | 0,48% | Ações |
| Diametric Capital, LP | $4.965.082 | 116.908 | 0,47% | Ações |
| WOODMONT INVESTMENT COUNSEL LLC | $4.748.571 | 111.810 | 0,44% | Ações |
| BANK OF AMERICA CORP /DE/ | $4.565.398 | 107.497 | 0,43% | Ações |
| FIRST TRUST ADVISORS LP | $4.260.378 | 100.315 | 0,40% | Ações |
| STATE OF WISCONSIN INVESTMENT BOARD | $4.146.219 | 97.627 | 0,39% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $3.934.590 | 92.644 | 0,37% | Ações |
| 12th Street Asset Management Company, LLC | $3.882.140 | 91.409 | 0,36% | Ações |
| Lumbard & Kellner, LLC | $3.835.975 | 90.322 | 0,36% | Ações |
| Steward Partners Investment Advisory, LLC | $3.832.960 | 90.251 | 0,36% | Ações |
| Bank of New York Mellon Corp | $3.625.366 | 85.363 | 0,34% | Ações |
| MILLENNIUM MANAGEMENT LLC | $3.575.210 | 84.182 | 0,33% | Ações |
| EQUITABLE TRUST CO | $3.371.184 | 79.378 | 0,32% | Ações |
| Squarepoint Ops LLC | $3.126.726 | 73.622 | 0,29% | Ações |
| DEUTSCHE BANK AG\ | $3.009.509 | 70.862 | 0,28% | Ações |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.004.668 | 70.748 | 0,28% | Ações |
Ativistas e proprietários de 5%+ 5 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Mark L. Baum ×3 declarações | 7 de Abril de 2025 | 10,69% | Emenda | · | SEC |
| 27 de Abril de 2021 | · | Declaração inicial | · | SEC | |
| Robert J. Kammer, as Trustee of The Robert J. Kammer Living Trust established 6/1/2000, Robert J. Kammer ×2 declarações | 30 de Agosto de 2016 | · | Declaração inicial | Investimento passivo | SEC |
| Dr. Robert J. Kammer ×2 declarações | 16 de Agosto de 2013 | · | Declaração inicial | · | SEC |
| DermaStar International, LLC ×7 declarações | 10 de Agosto de 2012 | · | Declaração inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 32 insiders · 10 diretores · 17 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Mark L. Baum | CHIEF EXECUTIVE OFFICER | 14 de Maio de 2026 P | 2.996.130 | 1 | 0 | $302.000 |
| John P. Saharek | CEO & President, ImprimisRx | 3 de Abril de 2025 M | 467.388 | 0 | 0 | $0 |
| Juliet Singh | CEO, Director and President | 18 de Junho de 2009 A | 1.954.125 | 0 | 0 | $0 |
| Andrew Boll | PRESIDENT AND CFO | 14 de Maio de 2026 P | 814.679 | 1 | 0 | $104.650 |
| Clayton D Edwards | Chief Operating Officer | 13 de Abril de 2017 A | · | 0 | 0 | $0 |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | 14 de Agosto de 2026 M | 0 | 0 | 1 | $-450.000 |
| Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | 30 de Janeiro de 2026 A | · | 0 | 0 | $0 |
| Randall E. Pollard | CHIEF ACCOUNTING OFFICER | 1 de Setembro de 2025 A | · | 0 | 0 | $0 |
| Joachim Ph Schupp | CHIEF MEDICAL OFFICER | 1 de Abril de 2013 A | · | 0 | 0 | $0 |
| Terry Nida | Chief Business Officer | 26 de Fevereiro de 2010 A | · | 0 | 0 | $0 |
| Perry J. Sternberg | Conselheiro | 18 de Junho de 2026 A | · | 0 | 0 | $0 |
| Adrienne L Graves | Conselheiro | 18 de Junho de 2026 A | 1.000 | 1 | 0 | $31.070 |
| Lauren P Silvernail | Conselheiro | 18 de Junho de 2026 A | 1.000 | 1 | 0 | $31.000 |
| Martin A. Makary | Conselheiro | 14 de Junho de 2024 A | 45.000 | 0 | 0 | $0 |
| Teresa Sparks | Conselheiro | 21 de Junho de 2023 A | · | 0 | 0 | $0 |
| Lawrence R. Van Horn | Conselheiro | 21 de Junho de 2023 A | 1.860 | 0 | 0 | $0 |
| Richard L Lindstrom MD | Conselheiro | 30 de Setembro de 2022 S | 26.100 | 0 | 0 | $0 |
| Robert J Kammer | Conselheiro | 25 de Junho de 2021 A | 797.327 | 0 | 0 | $0 |
| Anthony Principi | Conselheiro | 28 de Setembro de 2020 M | 93.798 | 0 | 0 | $0 |
| Stephen G Austin | Conselheiro | 16 de Março de 2020 M | 91.987 | 0 | 0 | $0 |
| William H. Nelson | Conselheiro | 10 de Junho de 2016 A | 12.904 | 0 | 0 | $0 |
| August Shelby Bassani | Conselheiro | 4 de Setembro de 2014 A | 13.488 | 0 | 0 | $0 |
| Peter C Kenny | Conselheiro | 2 de Outubro de 2013 A | 8.947 | 0 | 0 | $0 |
| Paul Finnegan | Conselheiro | 27 de Junho de 2013 A | 6.865 | 0 | 0 | $0 |
| Jeffrey J Abrams | Conselheiro | 27 de Junho de 2013 A | 45.927 | 0 | 0 | $0 |
| Opaleye Management Inc. | Detentor de 10% | 4 de Março de 2026 S | 59.428 | 0 | 6 | $-9.183.890 |
| Donald Paul Miloni | Detentor de 10% | 19 de Maio de 2015 S | 468.576 | 0 | 0 | $0 |
| DERMASTAR INTERNATIONAL, LLC | Detentor de 10% | 12 de Julho de 2012 J | 0 | 0 | 0 | $0 |
| John N Bonfiglio | · | 20 de Outubro de 2010 A | 50.000 | 0 | 0 | $0 |
| John T Lomoro | · | 19 de Junho de 2009 A | · | 0 | 0 | $0 |
| Lynn C Swann | · | 21 de Novembro de 2008 A | 25.000 | 0 | 0 | $0 |
| Anthony S Thornley | · | 21 de Novembro de 2008 A | 60.900 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 32 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,23% | 6.543 NS | 31 de Julho de 2026 | N-PORT |
| IWC · iShares Trust | 0,28% | 110.031 SH | 11 de Setembro de 2026 | Diário |
| IHE · iShares Trust | 0,28% | 122.556 SH | 11 de Setembro de 2026 | Diário |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,25% | 82.646 NS | 31 de Julho de 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,12% | 41.081 NS | 31 de Julho de 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 34.722 SH | 19 de Agosto de 2026 | Diário |
| FSMD · FIDELITY COVINGTON TRUST | 0,08% | 50.393 NS | 31 de Julho de 2026 | N-PORT |
| IWO · iShares Trust | 0,08% | 302.749 SH | 11 de Setembro de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,08% | 2.662 SH | 1 de Outubro de 2026 | Diário |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 7.488 NS | 31 de Julho de 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 7.406 NS | 31 de Julho de 2026 | N-PORT |
| RSSL · Global X Funds | 0,04% | 15.475 NS | 31 de Julho de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 186.298 SH | 19 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,04% | 826.648 SH | 11 de Setembro de 2026 | Diário |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 2.979 SH | 1 de Outubro de 2026 | Diário |
| ISCG · iShares Trust | 0,03% | 8.739 SH | 11 de Setembro de 2026 | Diário |
| DFAS · Dimensional ETF Trust | 0,03% | 125.599 NS | 31 de Julho de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 383.679 SH | 19 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,02% | 94.953 SH | 19 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 15.109 NS | 31 de Julho de 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 2.287 SH | 11 de Setembro de 2026 | Diário |
| DXUV · Dimensional ETF Trust | 0,01% | 949 NS | 31 de Julho de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,01% | 61.585 NS | 31 de Julho de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 10.408 NS | 31 de Julho de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 2.739 NS | 31 de Julho de 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 11.363 NS | 31 de Julho de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 45.401 SH | 11 de Setembro de 2026 | Diário |
| IWV · iShares Trust | 0,00% | 7.042 SH | 4 de Setembro de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.001.445 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.637 SH | 19 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | · | 1.222 SH | 11 de Setembro de 2026 | Diário |
| SMLF · iShares Trust | · | 34.093 SH | 11 de Setembro de 2026 | Diário |
HROW Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
classificação · 14 analistas
COMPRA
Alvo mediano
$60.00
+96,9%
5 35,7%
Compra forte
8 57,1%
Compra
1 7,1%
Manter
0 0,0%
Venda
0 0,0%
Venda forte
Preço-alvo de 12 meses
9 analistas · 2026-09-29Alvo médio $65.00 +113,3%
← Abaixo de todos os alvos
Preço atual $30.48
Mín$45.00
Média$65.00
Máx$88.00
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
| AVLN | · | · | · | · | · | · |
| LBRX | $563M | -7.1 | · | · | -25.5% | · |
| YARW | · | · | · | · | · | · |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | · |
| SPTX | · | · | · | · | · | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Fonte: SEC 10-Q arquivado Ago 10, 2026